Docetaxel in Treating Patients With Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

March 31, 2006

Study Completion Date

January 31, 2007

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.

DRUG

Docetaxel

35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.

Trial Locations (2)

77030-4009

MD Anderson Cancer Center at University of Texas, Houston

University of Texas M.D. Anderson CCOP Research Base, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00008411 - Docetaxel in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter